SEC Form 4 · accession 0001327111-26-000006
Lyell Immunopharma, Inc. · LYEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lynn Seely
Officer — President and CEO · Director
Period of report
Aug 21, 2026
Accepted (ET)
Aug 25, 2026 · 4:06 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001806952
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 21, 2026 | S | 9,589 | $15.54 | D | 63,899 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.